AzTrials
AzTrials

Benign Prostatic Hyperplasia With Lower Urinary Tract SymptomsNCT07416227

Comparison Between Water Vapor Thermal Therapy and Prostatic Artery Embolization in Treatment of Benign Prostatic Hyperplasia

A study testing Rezum and Prostatic Artery Embolization in people with Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms, run by Ain Shams University at 1 site in Egypt.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to compare the effectiveness of Rezum therapy versus Prostatic Artery Embolization in managing moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), with the primary endpoint being the improvement in the International Prostate Symptom Score (IPSS)… Read more about this study

Who is it for?
Ages 50 years and older, men only
What is being tested?
Rezum and Prostatic Artery Embolization
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteEgypt
Study dates
1 Oct 2025to 1 Oct 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥50 years.
  • IPSS ≥13.
  • Prostate volume between 30-80 mL.
  • Maximum urinary flow rate (Qmax) ≤15 mL/sec in patients with voiding LUTs.
  • Patients not responding to medical treatment.

Who cannot join

  • History or suspicion of prostate cancer.
  • Previous prostate surgery or minimally invasive BPH intervention.
  • Neurological bladder dysfunction.
  • Active urinary tract infection.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Seif AbdElmomen Yosef, MBBCh, MSc Faculty of Medicine contact

01093390291

siefabdelmomen@gmail.com

Egypt1 site, 1 recruiting
  • Ain Shams University

    Cairo, Abbassia, 00202

    Recruiting

Other trials in Egypt

About this study

The aim of this study is to compare the effectiveness of Rezum therapy versus Prostatic Artery Embolization in managing moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), with the primary endpoint being the improvement in the International Prostate Symptom Score (IPSS) over a 6-month follow-up period. Secondary endpoints include changes in post-void residual urine (PVR), maximum urinary flow rate (Qmax), patient-reported quality of life (QoL), and the preservation of ejaculatory and overall sexual function as assessed by validated questionnaires. This study aims to provide evidence-based guidance for optimizing treatment strategies for men with BPH, particularly those seeking alternatives to pharmacological therapy.

Read the detailed description

The aim of this study is to compare the effectiveness of Rezum therapy versus Prostatic Artery Embolization in managing moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), with the primary endpoint being the improvement in the International Prostate Symptom Score (IPSS) over a 6-month follow-up period. Secondary endpoints include changes in post-void residual urine (PVR), maximum urinary flow rate (Qmax), patient-reported quality of life (QoL), and the preservation of ejaculatory and overall sexual function as assessed by validated questionnaires. This study aims to provide evidence-based guidance for optimizing treatment strategies for men with BPH, particularly those seeking alternatives to pharmacological therapy.

A RCT will be conducted, including a minimum of 30 patients (15/group), will be enrolled over a two-year period with the final sample size depending on the number of eligible patients available during the study period, to compare the effectiveness of Rezum therapy versus Prostatic Artery Embolization in managing moderate-to-severe lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).

Participants will be assigned in a 1:1 ratio to either Rezum group or the prostatic artery embolization group by randomization using closed envelope technique.

All patients will be subjected to full history taking and physical examination. Radiology investigation will include pelvi-abdominal ultrasonography. Laboratory investigation will include urine analysis, urine culture and sensitivity if indicated, Serum Prostatic specific antigen (serum PSA). Routine preoperative laboratories included serum creatinine, serum urea, CBC, liver function tests and coagulation profile in both groups. The total amount of withdrawn blood for these routine laboratory investigations will be about 10-15 ml of venous blood from each patient.

Diagnosis of BPH patients who are eligible for the study will be confirmed by physical examination (including enlarged prostate with smooth surface, firm consistency with no suspicious nodules, preserved median sulcus and good anal tone) , PAUS with prostate size over 30 gram with no suspicious lesions , serum PSA below 4 ng/mL or suspicious psa but confirmed to be benign by Multiparametric MRI prostate protocol and/or transrectal ultrasound guided prostate biopsy.

The patients will be allocated into two equal groups by randomization. Group A (Rezum group), group B (prostatic artery embolization group). As regard Rezum group all procedures will be performed with only sedation or under general anathesia according to the patient preference and anathesiologist recommendations in a lithotomy position.

A single-use transurethral delivery device with an 18-gauge retractable needle is used to inject steam into the targeted area with a fixed depth of 10.25 mm via 12 emitter holes spaced at the needle tip with an angle of 120°.

The procedure is visualized using an integrated cystoscope with a standard 4 mm 30° lens.

Saline irrigation is used to improve visualization and to cool down the urethral surface during the procedure.

Injection starts 1 cm distal to the bladder neck at 3 and 9 o'clock positions. Each injection deploys 0.5 ml of steam over 9 s at 103 °C raising the tissue temperature to 70 °C and it is recommended to wait for a couple of seconds postinjection to avoid loss of vapor through the puncture site.

After each injection, the needle is retracted and reinserted 1 cm distal to the previous injection until the proximal edge of the verumontanum creating tissue ablation along the prostatic urethra. [5] As regard Prostatic artery embolization group patients will undergo the procedure under local anathesia.

The Patients will lie in supine position wearing the hospital gown. Sterilization of the groin will be done then puncture of the right femoral and/or left femoral artery will be done using puncture set after local anathesia.

6F vascular sheath, then a 5F cobra head catheter will be introduced in right and/or left femoral artery to catheterize one of the internal iliac artery then catheterizing its anterior division.

An ipsilateral oblique view (30-40 degrees) and/or cranio-caudal view (10 degrees) will be obtained for differentiation of prostatic artery from other branches of anterior division \& for identification of prostatic artery origin.

Selective catheterization of prostatic artery with suitable type of micro catheter and adjusted microwire angle.

Injection of 3ml of contrast through micro catheter to ensure the micro catheter position and no reflux occurs.

Embolizing material (400-500 micron microspheres) will be injected slowly and cautiously to avoid reflux under fluoroscopy guidance.

Intraoperative data:

Operative time, bleeding and any intraoperative events will be recorded.

Postoperative:

Hospitalization time and early post-operative complication will be recorded.

Follow up:

Patients will be followed at 1, 3, 6 months post-initiation of treatment. Assessments at each visit will include IPSS and QoL questionnaire, uroflowmetry and pelvic ultrasound to assess the prostate volume and post voiding residual urine.

Results" All intra, post-operative data and follow up results will be analyzed and assessed by the surgeon.

Being tested
Rezum, Prostatic Artery Embolization
Keywords
Comparison between Water Vapor Thermal Therapy and Prostatic Artery Embolization in treatment of Benign Prostatic Hyperplasia, Rezum vs Prostatic artery embolization in the treatment of Benign prostatic hyperplasia with lower urinary tract symptoms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • RezumProcedure or surgery

    A single-use transurethral delivery device with an 18-gauge retractable needle is used to inject steam into the targeted area with a fixed depth of 10.25 mm via 12 emitter holes spaced at the needle tip with an angle of 120°.

    The procedure is visualized using an integrated cystoscope with a standard 4 mm 30° lens.

    Saline irrigation is used to improve visualization and to cool down the urethral surface during the procedure.

    Injection starts 1 cm distal to the bladder neck at 3 and 9 o'clock positions. Each injection deploys 0.5 ml of steam over 9 s at 103 °C raising the tissue temperature to 70 °C and it is recommended to wait for a couple of seconds postinjection to avoid loss of vapor through the puncture site.

    After each injection, the needle is retracted and reinserted 1 cm distal to the previous injection until the proximal edge of the verumontanum creating tissue ablation along the prostatic urethra.

  • Prostatic Artery EmbolizationProcedure or surgery

    Sterilization of the groin will be done then puncture of the right femoral and/or left femoral artery will be done using puncture set after local anathesia.

    6F vascular sheath, then a 5F cobra head catheter will be introduced in right and/or left femoral artery to catheterize one of the internal iliac artery then catheterizing its anterior division.

    An ipsilateral oblique view (30-40 degrees) and/or cranio-caudal view (10 degrees) will be obtained for differentiation of prostatic artery from other branches of anterior division \& for identification of prostatic artery origin.

    Selective catheterization of prostatic artery with suitable type of micro catheter and adjusted microwire angle.

    Embolizing material (400-500 micron microspheres) will be injected slowly and cautiously to avoid reflux under fluoroscopy guidance.

Study groups in NCT07416227
Study groupRoleWhat they receive
Arm A - Water Vapor Thermal Therapy (Rezum) groupExperimentalprocedures will be performed with only sedation or under general anathesia according to the patient preference and anathesiologist recommendations in a lithotomy position. A single-use transurethral delivery device with an 18-gauge retractable needle is used to inject steam into the targeted area. The procedure is visualized using an integrated cystoscope with a standard 4 mm 30° lens. Saline irrigation is used to improve visualization and to cool down the urethral surface during the procedure. Injection starts 1 cm distal to the bladder neck at 3 and 9 o'clock positions. Each injection deploys 0.5 ml of steam over 9 s at 103 °C raising the tissue temperature to 70 °C and it is recommended to wait for a couple of seconds postinjection to avoid loss of vapor through the puncture site. After each injection, the needle is retracted and reinserted 1 cm distal to the previous injection until the proximal edge of the verumontanum creating tissue ablation along the prostatic urethra.
Receives: Procedure: Rezum
Arm B - Prostatic Artery Embolization (PAE)Active comparatorPatients will undergo the procedure under local anathesia. The Patients will lie in supine position and sterilization of the groin will be done then puncture of the right femoral and/or left femoral artery will be done using puncture set after local anathesia. 6F vascular sheath, then a 5F cobra head catheter will be introduced in right and/or left femoral artery to catheterize one of the internal iliac artery then catheterizing its anterior division. An ipsilateral oblique view (30-40 degrees) and/or cranio-caudal view (10 degrees) will be obtained for differentiation of prostatic artery from other branches of anterior division \& for identification of prostatic artery origin. Selective catheterization of prostatic artery with suitable type of micro catheter and adjusted microwire angle. Embolizing material (400-500 micron microspheres) will be injected slowly and cautiously to avoid reflux under fluoroscopy guidance.
Receives: Procedure: Prostatic Artery Embolization

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Improvement in the International Prostate Symptom Score (IPSS) over a 6-month follow-up period.

    Changes in a International Prostate Symptom Score (IPSS) will be measured to assess the degree of improvement after each procedure. Reduction of the score more than that it was before the procedure means better results and vice versa.

    (0-7) means mild symptoms , (8-19) means moderate symptoms and (20-35) means severe symptoms.

    The Unit of measure is a score .

    Measured: 6 months follow up for each patient following the procedure

Secondary outcomes (1)
  1. 1-Changes in post-voiding residual urine (PVR) assed by pelviabdomenal ultrasound in (mL) 2-Maximum urinary flow rate (Qmax) assessed by Uroflowmetry in (mL/s) 3-The preservation of ejaculatory function assessed by a validated questionnaire (MSHQ-EJD).

    1. Post voiding residual urine will be assessed by PelviAbdomenal ultrasonography and the lower post voiding residual urine the more improvement and unit of measure is milliliter (mL).
    2. maximum urinary flow rate will be assessed by uroflowmetry and the higher the maximum flow rate the more improvement and the unit of measure is milliliter(s)/second (mL/s).
    3. Preservation of ejaculatory function will be assessed by asking the patient him self to compare his ejaculatory function pre and post procedure by a validated questionnaire (Male sexual health questionnaire) [MSHQ-EjD] and the unit of measure for this is a questionnaire.

    Measured: 6 months follow up for each patient following the procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2026
  2. Study start1 Oct 2025
  3. Primary completion1 Oct 2027 (estimated)
  4. Study completion1 Oct 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Comparison between Water Vapor Thermal Therapy and Prostatic Artery Embolization in treatment of Benign Prostatic Hyperplasia
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07416227
Sponsor's protocol ID
FMASU MD295/2025
Status last verified
Feb 2026
First submitted
5 Dec 2025
Last updated
18 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Rezum and Prostatic Artery Embolization in people with Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Seif AbdElmomen Yosef, MBBCh, MSc Faculty of Medicine (01093390291, siefabdelmomen@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Improvement in the International Prostate Symptom Score (IPSS) over a 6-month follow-up period. (time frame: 6 months follow up for each patient following the procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in